DCM
TERN

DAFNA Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

DAFNA Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-86,000
Closed -$586K – 87
2024
Q2 		$586K Buy
+86,000
New +$521K 0.14% 71

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DAFNA Capital Management's TERN Position: Q3 2024 in Review

DAFNA Capital Management sold out of Terns Pharmaceuticals (TERN) in Q3 2024, closing a stake of 86,000 shares — an estimated $586K sold.

DAFNA Capital Management first reported a position in TERN in Q2 2024 and held it in 1 quarter. The position peaked at $586K in Q2 2024. 156 funds tracked by Wall St. Rank hold TERN as of Q3 2024.

  • DAFNA Capital Management reported no remaining Terns Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • DAFNA Capital Management sold 86,000 Terns Pharmaceuticals shares in Q3 2024, an estimated $586K.
  • DAFNA Capital Management first reported a position in Terns Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • DAFNA Capital Management's Terns Pharmaceuticals position peaked at $586K in Q2 2024.
  • 156 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2024.

Based on DAFNA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.